Key facts
- It has raised $42.3M across 3 recorded rounds; the latest was Early Stage VC ($10.6M) in Dec 2023.
- Notable investors include Impact Assets, Endless Frontier Labs, The Engine, Safar Partners, Engine Ventures — 11 tracked in total.
- Lucy Therapeutics has filed 5 Form Ds with the SEC since 2019, most recently May 2024 ($10.6M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Lucy Therapeutics
Funding rounds
3 roundsAbout Lucy Therapeutics
Developer of proprietary mitochondrial-based small molecule therapies and diagnostic biomarkers designed for the central nervous system. The company offers genetic technologies providing unparalleled insights into personalized medicine and improving patient outcomes, enabling healthcare industry to harness the power of genomics for precise healthcare interventions and better overall well-being.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 12
- Website
- lucytherapeutics.com/
- Ownership
- Privately Held (backing)
Lucy Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lucy Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lucy Therapeutics in its N-PORT filings yet. We sweep new filings monthly.